Whitepapers Considerations for Managing Clinical Trials and Regulatory Filing Strategy During COVID-19 Apr 15, 2021 Posted by Certara
Whitepapers Using Type 9 NDA Designation to Accelerate Multiple Approvals for Your Drug Product Apr 15, 2021 Posted by Certara
Whitepapers Simcyp PBPK for Drug-Drug Interactions (DDIs): A Regulatory Imperative Apr 08, 2021 Posted by Certara
Whitepapers The Effects of COVID-19 on Stakeholder Engagement & Value Communication: Preparing for the New Normal Apr 06, 2021 Posted by Certara
Whitepapers “Where do I start?”: Strategies for selecting the first dose for human clinical trials Apr 06, 2021 Posted by Certara